Troxerutin

Other Names

2-[3,4-Bis(2-hydroxyethoxy)phenyl]-3-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-7-(2-hydroxyethoxy)-4H-1-benzopyran-4-one3',4',7-Tri(hydroxyethyl)rutoside3',4',7-Tris(hydroxyethyl)rutin3',4',7-Tris[O-(2-hydroxyethyl)]rutin3-[(6-O-alpha-L-Rhamnopyranosyl-beta-D-glucopyranosyl)oxy]-3',4',7-tris(2-hydroxyethoxy)-5-hydroxyflavone5-Hydroxy-3-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-3',4',7-tris(2-hydroxyethoxy)flavone7,3',4'-TrihydroxyethylrutosideFactor P-zymaHydroxyethylrutosideNSC-758937PherarutinPosorutinTHRTri(hydroxyethyl)rutosideTrihydroxyethylrutinTrihydroxyethylrutosideTrioxyethylrutinTris(hydroxyethyl)rutinTris(hydroxyethyl)rutosideTris-O-(beta-hydroxyethyl)rutosideTroxerutinaTroxerutineTroxerutinumTRXVitamin P4Z-6000троксерутинتروكسيروتينトロキセルチン曲克芦丁

Synopsis

Troxerutin: A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Sources

1.1 Chemical Names and Classification

Troxerutin is a semi-synthetic flavonoid derived from rutin, a naturally occurring bioflavonoid found in sources such as tea, coffee, cereal grains, fruits, and vegetables, and is chemically known as 3',4',7-tris[O-(2-hydroxyethyl)]rutin with the molecular formula C₃₃H₄₂O₁₉. It is categorized as a 5-hydroxyflavonoid and flavonoid-3-O-glycoside. It has a molecular weight of roughly 742.68 g/mol (PubChem ID: 5486699).

Troxerutin is a flavonol, a type of flavonoid, derived from rutin; it is more accurately described as a hydroxyethylrutoside. It is a mixture of semisynthetic hydroxyethylrutosides (HERs) arising from the hydroxyethylation of rutin, a naturally occurring flavonoid. It is commonly known as vitamin P4.

Hydroxyethyl rutoside — also known as troxerutin — belongs to the γ-benzopyrone (flavonoid) subclass and can be further placed alongside diosmin and hesperidin as a flavonol-type venoactive compound.

1.2 Botanical Origin

Troxerutin is a semi-synthetic derivative obtained through chemical modification of rutin, a naturally occurring flavonoid glycoside primarily isolated from the flower buds of Sophora japonica (Japanese pagoda tree). Sophora japonica, or Japanese pagoda tree, is a deciduous tree with extracts used in traditional medicine for centuries. It is derivative of rutin, flavonoids extracted from Sophora japonica, a plant used in traditional Chinese medicine.

Rutin, the base compound, is extracted from plant materials using methods such as solvent extraction with ethanol or water, often enhanced by ultrasound or subcritical water techniques to improve yield and efficiency. Additionally, rutin occurs in low concentrations in various foods and beverages, including tea, coffee, cereals like buckwheat, and fruits and vegetables such as apples, citrus, onions, and broccoli.

1.3 Synthesis: From Rutin to Troxerutin

The primary method for producing troxerutin involves the hydroxyethylation of rutin, where ethylene oxide is reacted with the hydroxyl groups of rutin under alkaline conditions, typically catalyzed by sodium hydroxide, to form a mixture of hydroxyethylrutosides. This process was first described in 1961 by the Swiss pharmaceutical company Zyma S.A. The tri-(hydroxyethyl) ether of rutin derivative (troxerutin) was synthesized by reacting rutin at high temperature with a hydroxyethylation agent in the presence of a catalyst. The derivatives obtained were highly soluble, non-toxic, and demonstrated the following pharmacological properties: returning capillary permeability to normal, increasing capillary resistance, and presenting hemostatic and anti-inflammatory action.

Troxerutin functions primarily as a venotonic agent, exhibiting enhanced water solubility compared to rutin, and is administered orally or topically for its vascular protective effects. Troxerutin is a fraction of oxerutine. Absorbed by the digestive tract, oxerutine has a half-life of 24 hours and is principally excreted in bile.

1.4 Common Preparations and Trade Names

Its capsule and gel dosage forms are available internationally under the trade name Troxevasin®. Troxerutin is also known by the trade names Venoruton and Troxevasin. It is also used in topical products, together with Ginkgo biloba leaf extract, as an analgesic for temporary relief of pain, swelling, and bruising. Troxerutin is available in various pharmaceutical forms, including capsules, tablets, creams, and gels.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine Context

Hydroxyethylrutosides are derivatives of rutin, which is extracted from Sophora japonica, a plant used in traditional Chinese medicine. Sophora japonica is a deciduous tree with extracts used in traditional medicine for centuries. The base compound of troxerutin — rutin — was long used in East Asian herbal traditions, where the dried flower buds and fruits of Sophora japonica (known in Chinese as Huái Huā or Huái Jiǎo) were employed for conditions involving blood vessel fragility, bleeding, and inflammation.

Rutin is a natural antioxidant found in a variety of Chinese medicine herbs, fruits, and vegetables consumed daily. The parent flavonoid rutin itself had been recognized in European and Asian botanical traditions as a component of "vitamin P" — a group of plant pigments (later understood to be flavonoids) associated with maintaining capillary integrity. These compounds were previously defined as "vitamin P" or factor P (permeability), as flavonoid deficiency was found to result in capillary fragility and increased vessel wall permeability in animals. These appellations are now considered obsolete.

2.2 Transition from Traditional to Pharmaceutical Use

Troxerutin as such is not a traditional herbal remedy in the strict sense; it is a semi-synthetic compound created in the modern pharmaceutical era. Troxerutin, a trihydroxyethylated derivative of rutin, was synthesized and intravenously injected to treat chronic venous insufficiency diseases in China. Troxerutin and cerebroprotein hydrolysate (TCH) injections have been extensively used in clinics in China for the treatment of traumatic brain injury (TBI) and cerebral stroke. In the European pharmaceutical tradition, troxerutin gained wide use from the 1960s onward as a venotonic and capillary-protective agent for the management of venous circulatory disorders, building on the long European tradition of using rutin-containing plant extracts for similar purposes.

3. Key Constituents and Active Compounds

3.1 Structural Identity

Troxerutin is itself the principal active compound of interest rather than a complex extract containing multiple actives. It is a mixture of semisynthetic hydroxyethylrutosides arising from hydroxyethylation of rutin, a naturally occurring flavonoid. The hydroxyethylation of the rutin molecule at positions 3', 4', and 7 — introducing hydroxyethyl (–OCH₂CH₂OH) groups in place of free hydroxyl groups — substantially improves the compound's water solubility and modifies its pharmacokinetic profile relative to the parent molecule rutin.

Troxerutin (TRX) (3',4',7-tris[O-(2-hydroxyethyl)]rutin) is a water-soluble derivative of the bioflavonoid rutin extracted from the Japanese pagoda tree, which is also found abundantly in tea, coffee, vegetables, and fruits. The polyphenolic core structure, featuring a benzopyranone (flavone) skeleton with a disaccharide (rutinose = glucose + rhamnose) moiety, underpins the antioxidant and protein-binding characteristics of the molecule.

3.2 Relationship to Rutin and Quercetin

Rutin itself is the 3-O-rutinoside of quercetin. Troxerutin modifies the free hydroxyl groups of rutin through hydroxyethylation, yielding a compound with higher solubility but a similar flavonol core. Troxerutin is partially metabolized in the liver to form glucuronide and trihydroethylquercetin. This metabolic conversion back toward quercetin-type compounds may partially explain certain pharmacological overlaps with quercetin seen in preclinical studies.

4. Mechanisms of Action

4.1 Antioxidant Mechanisms

Troxerutin scavenges superoxide, nitric oxide, and other model stable radicals such as 1,1-diphenyl-2-picryl-hydrazyl and 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid. It also reacts with hydroxyl radicals, carbonate, and thiocyanate anions.

The antioxidant activity of troxerutin is mainly mediated through inhibition of NOX2 and stimulation of the Nrf2 signaling pathway, resulting in reduction in reactive oxygen species (ROS) production and improvement in antioxidant capacity. Troxerutin increases antioxidant enzymes and reduces oxidative damage, decreases proapoptotic proteins (APAF-1, BAX, caspases-9 and -3), and increases the antiapoptotic BCL-2, while also increasing the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and downregulating nuclear factor κB (NF-κB).

4.2 Anti-Inflammatory Mechanisms

Hydroxyethylrutosides inhibit the recruitment and activation of neutrophils by endothelium activated during blood stasis. The most important pharmacological action of oxerutins — of which troxerutin is a component — is the inhibition of microvascular permeability and reduction of edema.

In order to prevent renal injury from inflammatory responses, troxerutin suppresses the expression of OX-2, iNOS, and NF-κB via inhibition of NLRP3, CXCR4, and TXNIP. A large number of pharmacological and clinical studies of oxerutin showed its influence on disturbances of capillary permeability, effects on erythrocyte membrane and RBC deformation and aggregation. Beneficial effects on antiedematous actions and inhibition of prostaglandin synthesis have also been reported.

4.3 Vascular and Rheological Mechanisms

Troxerutin is thought to inhibit red cell and platelet aggregation, improve erythrocyte deformability, and improve plasma viscosity and retinal microcirculation. Other mechanisms of action have been claimed, involving inhibition of hyaluronidase and histamine synthesis at the vascular wall, and decreased blood viscosity and erythrocyte aggregation. The profibrinolytic and rheological activities of troxerutin have been shown to correlate well with its plasma levels.

Hydroxyethylrutosides protect the vascular endothelium and have a strong affinity for the venous wall. The diffusion and accumulation of these compounds in the venous wall have been demonstrated.

4.4 Neuroprotective Signaling

Troxerutin reduces acetylcholinesterase activity and upregulates the phosphoinositide 3-kinase/Akt signaling pathway in Alzheimer's disease models. Troxerutin administration diminishes glial fibrillary acid protein (GFAP) as a marker of astrogliosis, and DNA fragmentation, as well as inhibits the loss of nigral tyrosine hydroxylase (TH)-positive neurons. These neuroprotective effects are mediated by stimulation of estrogen receptor β (ERβ) and PI3K signaling pathways.

4.5 Anticancer Signaling Pathways

Troxerutin induces apoptosis, suppresses metastasis and oxidative stress, and modulates immunity via NF-κB, MAPK, and PI3K/AKT pathways. Studies are in line with the fact that troxerutin is capable of affecting molecular pathways such as NF-κB and MDM2 in cancer therapy. Troxerutin supplementation is associated with a decrease in the survival of gastric cancer cells and their sensitivity to 5-fluorouracil chemotherapy.

4.6 Complement Pathway Inhibition

Troxerutin may inhibit inadvertent cellular lysis and joint damage in cases of sterile inflammation by blocking C9 involvement in membrane attack complex (MAC) formation. Troxerutin has been widely reported to possess hepatoprotective as well as renoprotective properties which can be attributed to MAC inhibition, thus protecting hepatic and renal cells from xenobiotic-mediated lysis.

5. Scientific Evidence by Area of Use

5.1 Chronic Venous Insufficiency (CVI) and Vascular Disorders

As a member of the hydroxyethylrutosides class, troxerutin is widely utilized in the symptomatic management of chronic venous insufficiency (CVI), where it helps alleviate symptoms such as leg pain, swelling, and heaviness by improving venous tone, reducing capillary permeability, and inhibiting inflammation.

Human/Clinical Evidence: A randomized, double-blind, multicentre, prospective controlled trial evaluated the efficacy of troxerutin in chronic venous insufficiency. The study was conducted at Hôtel Dieu Hospital and Notre Dame de Bon Secours Hospital in Paris, France. Sixty-nine patients with truncal varicose veins participated. After a single-blind 15-day placebo run-in period, one group (n=34) received troxerutin 3500 mg daily for 2 months, while the other group (n=35) received a placebo. Leg aching (p < 0.001) and venous function score (p < 0.001) improvements were significantly higher in the troxerutin group (83% and −3.7) compared with the placebo group (23% and −0.7). A significant difference in favour of troxerutin was also found for erythrocyte aggregation kinetic indexes (p < 0.001) and dissociation threshold (p < 0.01).

In another double-blind study, 12 female post-menopausal patients with chronic venous insufficiency grade II participated, with random allocation to treatment groups. They received 900 mg/day oxerutins or troxerutin for 12 weeks and were observed for 4 further weeks without treatment.

A 2015 systematic review examined the broader hydroxyethylrutoside (HR) class. The search identified 1,474 records and only 15 trials involving 1,643 participants met the inclusion criteria. Overall, 1,052 participants received HR including troxerutin intervention and 591 participants received the control. All HR interventions were given orally (as capsules, powder, tablets, or solution), and the daily dose ranged from 0.6 to 4 g. The most frequently tested daily dose was 2 g, and the duration of the trials ranged from 4 to 12 weeks.

A 2025 systematic review and meta-analysis reported: Hydroxyethylrutoside showed significant benefits in pain reduction and resting flux improvement, with mean differences of 38 (95% CI: 10.56–65.44). Improvements in edema and quality of life were less consistent. Substantial heterogeneity was observed (I² = 100%, p < 0.001). Hydroxyethylrutoside emerges as a promising alternative for managing CVI; however, limitations such as high heterogeneity, small sample sizes, and methodological inconsistencies highlight the need for more robust and standardized clinical trials.

Venous Leg Ulcers (VLU): The evidence concerning the efficacy of hydroxyethylrutosides is based on limited data and small RCTs. In a systematic review of HR for the improvement of CVI signs and symptoms, four trials focusing on VLU patients were included. One trial comparing troxerutin vs. placebo in VLU treatment (with compression use in both groups) found a statistically significant difference with better outcomes in the troxerutin group (odds ratio, 2.91; 95% CI, 1.36–6.2). In a Cochrane analysis of flavonoids for treating VLUs, nine studies including four with HR were reported. The authors emphasized the limited quality of available data and an unclear risk of bias.

Evidence strength assessment: The clinical evidence for CVI symptom relief (leg pain, heaviness, edema) is supported by multiple randomized, double-blind, placebo-controlled trials, though trials are frequently small, of short duration, and methodologically heterogeneous. The evidence is considered promising but not definitive by current standards.

5.2 Hemorrhoidal Disease and Phlebological Conditions

Clinical trials have revealed the efficacy of troxerutin for management of phlebocholosis and hemorrhoidal diseases. Troxerutin is used to treat conditions such as venous insufficiency and hemorrhoids, and is claimed to reduce capillary fragility and lower blood viscosity. Clinical studies evaluating troxerutin supplementation have documented reductions in vascular permeability, edema formation, and inflammatory markers in individuals with chronic venous insufficiency and after surgical procedures.

Evidence strength assessment: Troxerutin's use in hemorrhoidal disease is supported by clinical trial evidence, though the body of dedicated human trials specifically in hemorrhoidal disease is smaller than in CVI. It has regulatory approval for this indication in several European and Asian countries.

5.3 Neuroprotection and Neurodegenerative Diseases

Preclinical Evidence (Animal Studies): A study investigated the possible neuroprotective effect of troxerutin in an animal model of Alzheimer's disease. The Alzheimer's model was induced by a single dose intracerebroventricular (ICV) injection of Aβ 1-42 (5 nmol/5 µl). Thereafter, troxerutin (300 mg/kg) was gavaged for 14 days. The findings revealed that troxerutin attenuates Aβ 1-42-induced deleterious effects in the hippocampus of rats, showing neuroprotective potential against Aβ 1-42-induced Alzheimer's disease, possibly through anti-apoptotic, antioxidant, and AChE-inhibitory effects in the hippocampus.

Troxerutin is considered an interesting drug candidate for multiple neurological disorders since it demonstrates antidepressant activity (because of its anti-inflammatory action), augments memory in animal models, and provides anxiolytic actions (by reducing serum cortisol level), and ameliorated the impairments of spatial learning and memory in a rat Alzheimer's model.

In a STZ-induced diabetic rat model, troxerutin improved cognitive dysfunction by enhancing SOD activity and increasing the content of Nrf2 as a core transcription factor of antioxidant proteins in the hippocampus.

Although troxerutin and cerebroprotein hydrolysate (TCH) injections have been extensively used in clinics in China for the treatment of traumatic brain injury (TBI) and cerebral stroke, the potential efficacy of TCH injection in the treatment of spinal cord injury has not been as fully elucidated.

Evidence strength assessment: Neuroprotective data for troxerutin is predominantly from animal models (rats and mice). While the results are mechanistically interesting and internally consistent, dedicated large human clinical trials for neurodegenerative diseases are lacking as of the available literature. The clinical use of troxerutin in China for TBI and stroke represents real-world application, but the controlled clinical evidence base is limited.

5.4 Diabetes and Metabolic Syndrome

Troxerutin is one of the pharmacological options studied for anti-diabetic activity. It has been revealed that troxerutin improves symptoms of insulin resistance and hyperlipidemia in diabetes via antioxidant activity.

Troxerutin has been shown in mice to reverse CNS insulin resistance and reduce reactive oxygen species induced by a high-cholesterol diet.

Zhang and coworkers evaluated the neuroprotective effect of troxerutin in T1DM rats. Troxerutin administration decreased escape latency and malondialdehyde (MDA) levels, while it enhanced glutamate cysteine ligase modifier (GCLM) and glutamate cysteine ligase catalytic (GCLC) levels as well as SOD activity and GSH levels.

Evidence strength assessment: Evidence for anti-diabetic effects of troxerutin is largely preclinical (rodent models). Human clinical trial data for diabetes as a primary outcome is not robustly established in the available literature. Some benefits in the setting of diabetic retinopathy have been noted in clinical use, particularly in Eastern European and Chinese clinical practice.

5.5 Hepatoprotection (Liver Protection)

The hepatoprotective effects of troxerutin in animal models were related to a decrease in lipid peroxidation levels and oxidative stress through elevating the activities of antioxidant enzymes as well as ameliorating the upregulation of NF-κB, iNOS, and COX-2 in the liver of D-galactose-treated rats. Treatment with troxerutin (5 and 10 mg/kg) for 6 days before gamma irradiation significantly reduced oxidative stress via increasing SOD activity and reducing MDA levels in mouse liver. Troxerutin (10 mg/kg) also decreased irradiation-induced pathological changes such as edema and necrosis in livers of affected mice.

Protective effects of troxerutin in Alzheimer's disease, colon carcinogenesis, and hepatocellular carcinoma have emerged in recent studies.

Evidence strength assessment: Hepatoprotective evidence is primarily from animal and in vitro studies. Human clinical trial data for liver disease as a primary indication is not currently well established in the peer-reviewed literature available.

5.6 Renal (Kidney) Protection

A study evaluated the protective effect of troxerutin against D-galactose-induced oxidative DNA damage in mouse kidney. The data showed that troxerutin significantly decreased levels of urea, uric acid, and creatinine in serum and reduced renal histological injury in D-gal-treated mice. Troxerutin markedly restored Cu/Zn-SOD, CAT, and GPx activities in the kidney. Furthermore, the increase of 8-hydroxydeoxyguanosine (a marker of oxidative DNA damage) induced by D-galactose was effectively suppressed by troxerutin.

In order to prevent renal injury from inflammatory responses, troxerutin suppresses the expression of OX-2, iNOS, and NF-κB via inhibition of NLRP3, CXCR4, and TXNIP.

Evidence strength assessment: Renal protective data is entirely preclinical (animal models). No dedicated human clinical trials in renal disease have been identified.

5.7 Cardiovascular Effects

Troxerutin preconditioning has been shown to protect against myocardial ischemia/reperfusion injury via the PI3K/Akt pathway in rat models. Troxerutin has attracted attention due to its favorable biological activities, including protection against ischemia/reperfusion injury, hepatoprotection, and neuroprotection.

Evidence strength assessment: Cardioprotective data is from animal (rat) models. Human clinical trial data specifically for myocardial protection is not established in the available literature.

5.8 Anticancer Effects

Troxerutin has gained increasing attention as a bioactive flavonoid with multifaceted anticancer properties. Research has indicated potential activity against breast, lung, liver, colorectal, prostate, and brain cancers. Troxerutin induces apoptosis, suppresses metastasis and oxidative stress, and modulates immunity via NF-κB, MAPK, and PI3K/AKT pathways. Poor bioavailability reduces the potency of therapeutic use, but novel nanoformulations may enhance its anticancer efficacy.

Evidence strength assessment: Anticancer evidence is exclusively preclinical — derived from in vitro cell-line studies and animal tumor models. No human clinical trials investigating troxerutin as an anticancer agent have been identified. This area remains exploratory.

5.9 Inflammatory Arthritis

In a study exploiting the antiarthritic properties of troxerutin using an adjuvant-induced arthritic (AIA) rat model, AIA-induced rats showed the highest arthritis score at disease onset; by oral administration of troxerutin (50, 100, and 200 mg/kg body weight), arthritis scores were reduced to basal level in a dose-dependent manner. Troxerutin is a known antioxidant and inhibits oxidative stress-mediated cellular apoptosis, and may protect the synovial joints alleviating severe damage in adjuvant-induced arthritis and possibly in rheumatoid arthritis patients.

Evidence strength assessment: Data is from a preclinical animal model. Human clinical evidence in arthritis is absent in the available literature.

5.10 Skin and Keratinocyte Effects

A 2018 study found that Sophora japonica extracts and troxerutin, one of the compounds present in these extracts, accelerated the differentiation of keratinocytes via miR-181a upregulation. The results suggest that S. japonica extracts can strengthen the skin's barrier by regulating keratinocyte differentiation and could play a role in treating conditions associated with an impaired skin barrier, such as eczema, psoriasis, and atopic dermatitis.

Troxerutin alleviates UV-B-induced apoptosis, cell growth arrest, migration restriction, proliferation inhibition, and DNA damage in cultured HaCaT human immortal keratinocytes.

Evidence strength assessment: Evidence is from in vitro studies and a preliminary in vitro/cell-based investigation. No human clinical trials for dermatological conditions have been identified.

6. Pharmacokinetics

6.1 Absorption and Bioavailability

Troxerutin is rapidly absorbed when the drug is taken orally. The maximum concentration of troxerutin in the blood plasma (Cmax) is established on average 1.75 ± 0.46 hours after oral administration. Absorption is approximately 10–15%. The bioavailability of the drug increases with increasing dose.

6.2 Half-Life and Elimination

The half-life (T½) is 6.77 ± 2.37 hours. The therapeutic concentration of the drug in the blood plasma is maintained for approximately 8 hours. Thirty hours after troxerutin administration, a second maximum concentration in blood plasma is observed due to enterohepatic recirculation. The compound is partially metabolized in the liver to form glucuronide and trihydroethylquercetin.

Troxerutin is excreted mainly through the intestine (up to 65–70%), and a smaller part (up to 25%) of the drug is excreted unchanged by the kidneys.

7. Dosage Forms and Doses Reported in Studies

Troxerutin is available in various forms, including capsules, tablets, creams, and gels.

Oral (CVI trials): All HR interventions in the 2015 systematic review were given orally (as capsules, powder, tablets, or solution), and the daily dose ranged from 0.6 to 4 g. The most frequently tested daily dose was 2 g, and the duration of the trials ranged from 4 to 12 weeks.
Oral (1994 double-blind trial): One group received troxerutin 3,500 mg daily for 2 months.
Oral (CVI comparison study): Patients received 900 mg/day oxerutins or troxerutin for 12 weeks.
Animal studies (Alzheimer's model): Troxerutin (300 mg/kg) was gavaged for 14 days in rat models.
Animal studies (arthritis): Oral administration of troxerutin at 50, 100, and 200 mg/kg body weight was used in the adjuvant-induced arthritic rat model.
Animal studies (liver/radiation protection): Treatment with troxerutin at 5 and 10 mg/kg for 6 days before gamma irradiation was used in mouse models.
Topical: When using troxerutin in cream or gel form for skin conditions like varicose veins or hemorrhoids, a thin coating is applied and gently massaged into the affected region.

8. Body Systems and Health Areas Associated with Troxerutin

Troxerutin exerts multiple biological functions, including antioxidant, anti-inflammatory, nephroprotective, antithrombotic, antidiabetic, and neuroprotective effects. The following organ systems and health areas have been investigated:

Vascular/Venous System: Chronic venous insufficiency, varicose veins, capillary fragility, edema, venous leg ulcers, and post-surgical venous complications.
Proctological: Hemorrhoidal disease and perianal inflammation.
Nervous System: Neuroprotection, Alzheimer's disease models, Parkinson's disease models, spinal cord injury, traumatic brain injury, cognitive function.
Metabolic/Endocrine: Insulin resistance, hyperlipidemia, diabetic retinopathy.
Hepatic (Liver): Protection from toxin-induced and radiation-induced liver injury.
Renal (Kidney): Protection from oxidative DNA damage and nephrotoxins.
Cardiovascular: Myocardial ischemia/reperfusion injury, platelet aggregation.
Oncology (Preclinical): Multiple cancer cell lines studied in vitro and in animal models.
Musculoskeletal: Inflammatory arthritis (animal models).
Dermatological: Skin barrier regulation, UV-B-induced cell damage (in vitro).

9. Safety Considerations and Drug Interactions

9.1 General Tolerability

Clinical trials on oxerutin showed that it is quite active in the treatment of chronic venous hypertension. Interestingly, no detected toxicities or side effects were noted in the oxerutin clinical trial results. Troxerutin is well tolerated, and inhibition of its possible molecular targets may have minimal or no adverse effects.

9.2 Documented Adverse Effects

According to Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (15th edition), troxerutin is a yellow substance, and a few cases of yellow discoloration of the skin — but not of the sclerae — have been observed. This discoloration can be mistaken for jaundice but vanishes when the drug is withdrawn.

The most commonly reported side effects include gastrointestinal disturbances such as nausea, stomach pain, and diarrhea. These symptoms are usually mild and often resolve on their own. Allergic reactions, though rare, can occur; symptoms may include itching, rash, or swelling, particularly of the face, tongue, or throat.

9.3 Anticoagulant/Antiplatelet Considerations

Troxerutin may have anticoagulant and antiplatelet effects. Individuals with active bleeding disorders, such as hemophilia or peptic ulcers, should avoid troxerutin as it might increase the risk of bleeding. Troxerutin should not be taken concurrently with anticoagulant medications like warfarin, heparin, or antiplatelet drugs like aspirin, as it may increase the risk of bleeding.

9.4 Pediatric and Pregnancy Considerations

Troxerutin's safety and efficacy in children have not been well studied, so it is generally not recommended for pediatric use without consulting a healthcare professional.

9.5 Potential Intravenous Risk

Troxerutin, a trihydroxyethylated derivative of rutin, has been used intravenously to treat chronic venous insufficiency diseases in China; however, serious side effects of troxerutin are reported in clinical practice with IV administration. This distinguishes the IV route from the generally well-tolerated oral and topical routes documented in European clinical trials.

9.6 Liver Function

Although rare, troxerutin can have an impact on liver function. Elevated liver enzymes have been reported in some cases, which may indicate liver inflammation or damage. Regular monitoring of liver function tests may be recommended for individuals on long-term troxerutin therapy.

9.7 Coumarin Combinations

Coumarin has been withdrawn from the market as a standalone agent for some indications because of drug-related hepatitis at high doses, except in brands associating low doses of coumarin and troxerutin. Combination preparations of coumarin plus troxerutin have been used clinically in some markets, with the troxerutin component contributing venotonic activity.

Summary of Evidence Quality

The clinical evidence base for troxerutin is strongest for its traditional indication as a venotonic and capillary-protective agent in chronic venous insufficiency, with multiple randomized double-blind placebo-controlled trials supporting symptomatic benefit, albeit with acknowledged limitations of sample size and heterogeneity. The related molecular details and mechanisms of troxerutin across its broader therapeutic applications remain poorly understood. The pharmacological impacts for anti-diabetic, neuroprotective, hepatoprotective, and anticancer properties have been demonstrated in in vitro and in vivo studies, but lack corroborating large human clinical trial evidence. Translating these findings to human clinical settings requires further rigorous investigation.

References

Health Conditions

Health conditions that Troxerutin may help support.

CirculationScientific
Troxerutin (O-β-hydroxyethyl rutin) is a semi-synthetic flavonoid venoactive drug used clinically in Europe and Asia for chronic venous insufficiency and microcirculatory disorders. Multiple RCTs have confirmed its efficacy in reducing leg oedema, capillary permeability, and venous symptoms. It was the reference comparator in four of the 17 horse chestnut Cochrane RCTs, demonstrating clinical-grade activity for venous circulation.
HemorrhoidsScientific
Troxerutin (hydroxyethylrutoside) is listed among hemorrhoid medications with established clinical evidence of effectiveness in a 2024 Molecules PMC review, and appeared in the 2006 British Journal of Surgery meta-analysis of phlebotonics for hemorrhoidal disease. A PubMed-listed clinical study on troxerutin specifically for hemorrhoids and post-hemorrhoidectomy RCTs further support its use.
Spider VeinsScientific
Troxerutin is a semi-synthetic hydroxyethylated derivative of rutin used clinically for chronic venous insufficiency, edema, and related conditions including spider veins. Double-blind RCTs show it reduces leg volume and subjective symptoms in CVI patients. It is a recognized venoactive compound in European pharmacological treatment guidelines.
Varicose VeinsScientific
Troxerutin is a semisynthetic derivative of rutin (a hydroxyethylrutoside) used in Europe as a venoactive drug for varicose veins and CVI. It is one component of the standardized oxerutin mixture approved for venous insufficiency. There is evidence from double-blind, placebo-controlled clinical studies that it improves leg aching, swelling, and fatigue in varicose veins, and Cochrane-registered studies document its use in varicose vein patients. EBSCO Research Starters confirms it may be effective when taken alone at 600–1,200 mg/day.

Body Systems

Body systems that Troxerutin may help support.

No body systems available.